Leerink Partnrs Has Positive Outlook for Cencora Q2 Earnings

Cencora, Inc. (NYSE:COR - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for shares of Cencora in a report issued on Thursday, January 2nd. Leerink Partnrs analyst M. Cherny now expects that the company will earn $4.23 per share for the quarter, up from their prior forecast of $4.12. The consensus estimate for Cencora's current full-year earnings is $14.93 per share. Leerink Partnrs also issued estimates for Cencora's Q3 2025 earnings at $3.87 EPS, Q4 2025 earnings at $3.84 EPS, FY2025 earnings at $15.39 EPS, FY2026 earnings at $17.11 EPS and FY2028 earnings at $20.75 EPS.

Other equities analysts have also issued research reports about the stock. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Evercore ISI upped their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. UBS Group increased their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Finally, StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $275.60.

Cencora Stock Down 0.2 %

Shares of Cencora stock traded down $0.51 during trading on Monday, hitting $228.69. 1,005,821 shares of the stock traded hands, compared to its average volume of 1,152,907. The stock has a market cap of $44.20 billion, a P/E ratio of 30.45, a PEG ratio of 1.54 and a beta of 0.49. The company has a fifty day moving average price of $237.34 and a two-hundred day moving average price of $233.53. Cencora has a twelve month low of $208.58 and a twelve month high of $253.27. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend was Friday, November 15th. Cencora's payout ratio is currently 29.29%.

Insider Activity

In other news, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,696 shares of company stock valued at $22,862,734. 15.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Arizona State Retirement System raised its stake in shares of Cencora by 6.3% in the 2nd quarter. Arizona State Retirement System now owns 52,047 shares of the company's stock valued at $11,726,000 after buying an additional 3,089 shares in the last quarter. Private Advisor Group LLC raised its position in Cencora by 11.5% in the second quarter. Private Advisor Group LLC now owns 6,785 shares of the company's stock worth $1,529,000 after purchasing an additional 700 shares in the last quarter. Candriam S.C.A. lifted its stake in Cencora by 21.9% during the second quarter. Candriam S.C.A. now owns 7,897 shares of the company's stock worth $1,779,000 after purchasing an additional 1,420 shares during the period. Savant Capital LLC boosted its holdings in Cencora by 2.1% during the second quarter. Savant Capital LLC now owns 6,511 shares of the company's stock valued at $1,467,000 after purchasing an additional 132 shares in the last quarter. Finally, SRS Capital Advisors Inc. grew its stake in shares of Cencora by 6.7% in the 2nd quarter. SRS Capital Advisors Inc. now owns 3,338 shares of the company's stock valued at $752,000 after purchasing an additional 210 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.